HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in
treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface
antigen (HBsAg) levels.